Diabetes Mellitus, Type IIPhase 3NCT00947557
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin
A Phase 3 study testing Dutogliptin in people with Diabetes Mellitus, Type II, run by Forest Laboratories at 147 sites in 8 countries.
Trial summary
This study will evaluate the safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM) who are receiving background therapy of glimepiride with or without metformin. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Diabetes Mellitus, Type II
- What is being tested?
- Dutogliptin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 677 participants
- Where
- 147 sitesin 8 countries
- Study dates
- Jul 2009to Jul 2010
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Type 2 diabetes mellitus, diagnosed at least 3 months prior to Screening (Visit 1)
- BMI 20 to 48 kg/m2, inclusive
- HbA1c 7.0% - 10.0%, inclusive
- Age 18 to 85 years, inclusive
Who cannot join
- Currently on 3 or more oral antidiabetic drugs or insulin.
- Type 1 diabetes mellitus
Trial locations and contacts
147 sites in 8 countries.
147 sites in 8 countries
United States98 sites
Forest Investigative Site 039
Akron, Ohio, 44311
Forest Investigative Site 101
Albuquerque, New Mexico, 87108
Forest Investigative Site 061
Anaheim, California, 92801
Forest Investigative Site 099
Arlington, Texas, 76014
Forest Investigative Site 045
Atlanta, Georgia, 30338
Forest Investigative Site 079
Augusta, Georgia, 30909
Forest Investigative Site 035
Baltimore, Maryland, 21204
Forest Investigative Site 083
Bethany, Oklahoma, 73008
Forest Investigative Site 064
Birmingham, Alabama, 35205
Forest Investigative Site 020
Birmingham, Alabama, 35235
Forest Investigative Site 156
Boca Raton, Florida, 33432
Forest Investigative Site 003
Brockton, Massachusetts, 02301
Forest Investigative Site 055
Brockton, Massachusetts, 23301
Forest Investigative Site 059
Chandler, Arizona, 85225
Forest Investigative Site 094
Charlotte, North Carolina, 28204
Forest Investigative Site 051
Charlotte, North Carolina, 28209
Forest Investigative Site 114
Chattanooga, Tennessee, 37404
Forest Investigative Site 104
Chattanooga, Tennessee, 37421
Forest Investigative Site 041
Chula Vista, California, 91911
Forest Investigative Site 023
Cincinnati, Ohio, 45242
Forest Investigative Site 043
Columbus, Ohio, 43201
Forest Investigative Site 056
Corpus Christi, Texas, 78404
Forest Investigative Site 034
Covington, Louisiana, 70433
Forest Investigative Site 071
Dallas, Texas, 75230
Forest Investigative Site 017
Dallas, Texas, 75235
Forest Investigative Site 057
Dayton, Ohio, 45406
Forest Investigative Site 004
Daytona Beach, Florida, 32117
Forest Investigative Site 002
Dearborn, Michigan, 48126
Forest Investigative Site 052
DeLand, Florida, 32720
Forest Investigative Site 088
Denver, Colorado, 80239
Forest Investigative Site 054
Edina, Minnesota, 55435
Forest Investigative Site 049
Encinitas, California, 92024
Forest Investigative Site 005
Eugene, Oregon, 97404
Forest Investigative Site 100
Evansville, Indiana, 47710
Forest Investigative Site 097
Evansville, Indiana, 47713
Forest Investigative Site 113
Gilbert, Arizona, 85295
Forest Investigative Site 022
Greenbrae, California, 94904
Forest Investigative Site 103
Greer, South Carolina, 29651
Forest Investigative Site 047
Harbor City, California, 90710
Forest Investigative Site 129
Hollywood, Florida, 33021
Forest Investigative Site 010
Huntington Park, California, 90255
Forest Investigative Site 014
Irving, Texas, 75039
Forest Investigative Site 062
Jacksonville, Florida, 32205
Forest Investigative Site 126
Jenkintown, Pennsylvania, 19046
Forest Investigative Site 053
Kansas City, Kansas, 66160
Forest Investigative Site 032
Kettering, Ohio, 45429
Forest Investigative Site 072
Las Vegas, Nevada, 89101
Forest Investigative Site 065
Las Vegas, Nevada, 89117
Forest Investigative Site 058
Lenoir, North Carolina, 28645
Forest Investigative Site 107
Lexington, Kentucky, 40504
Forest Investigative Site 096
Litchfield, Arizona, 85340
Forest Investigative Site 070
Los Angeles, California, 90057
Forest Investigative Site 001
Medford, Oregon, 97504
Forest Investigative Site 009
Meridian, Idaho, 83646
Forest Investigative Site 050
Miami, Florida, 33156
Forest Investigative Site 021
Miami, Florida, 33169
Forest Investigative Site 122
Miami, Florida, 33186
Forest Investigative Site 125
Miami Lakes, Florida, 33014
Forest Investigative Site 038
Morehead City, North Carolina, 28557
Forest Investigative Site 025
Muscle Shoals, Alabama, 35661
Forest Investigative Site 118
New Bedford, Massachusetts, 02740
Forest Investigative Site 081
New Hyde Park, New York, 11042
Forest Investigative Site 069
New Port Richey, Florida, 34652
Forest Investigative Site 016
New York, New York, 10019
Forest Investigative Site 111
Northridge, California, 91325
Forest Investigative Site 012
Ocala, Florida, 34471
Forest Investigative Site 015
Orlando, Florida, 32806
Forest Investigative Site 131
Ormond Beach, Florida, 32174
Forest Investigative Site 046
Oxon Hill, Maryland, 20745
Forest Investigative Site 033
Pelzer, South Carolina, 29669
Forest Investigative Site 127
Pembroke Pines, Florida, 33028
Forest Investigative Site 080
Peoria, Arizona, 85381
Forest Investigative Site 030
Peoria, Illinois, 61614
Forest Investigative Site 066
Philadelphia, Pennsylvania, 19152
Forest Investigative Site 098
Phoenix, Arizona, 85020
Forest Investigative Site 068
Renton, Washington, 98057
Forest Investigative Site 031
Riverside, California, 92506
Forest Investigative Site 091
Roseville, California, 95661
Forest Investigative Site 084
Roswell, Georgia, 30076
Forest Investigative Site 132
Roswell, Georgia, 30076
Forest Investigative Site 067
Sacramento, California, 95821
Forest Investigative Site 029
Saint Clair Shores, Michigan, 48081
Forest Investigative Site 040
Salisbury, North Carolina, 28144
Forest Investigative Site 076
Salt Lake City, Utah, 84107
Forest Investigative Site 109
San Antonio, Texas, 78229
Forest Investigative Site 119
San Antonio, Texas, 78258
Forest Investigative Site 112
Santa Ana, California, 92701
Forest Investigative Site 018
Sarasota, Florida, 34239
Forest Investigative Site 044
Scottsdale, Arizona, 85254
Forest Investigative Site 075
St. Petersburg, Florida, 33716
Forest Investigative Site 036
Tipton, Pennsylvania, 16684
Forest Investigative Site 028
Virginia Beach, Virginia, 23454
Forest Investigative Site 011
Walnut Creek, California, 94598
Forest Investigative Site 007
Waltham, Massachusetts, 24453
Forest Investigative Site 063
West Hills, California, 91307
Forest Investigative Site 026
West Palm Beach, Florida, 33401
Forest Investigative Site 008
Wichita, Kansas, 67203
Forest Investigative Site 082
Winston-Salem, North Carolina, 27103
India18 sites
Forest Investigative Site 618
Ahmedabad, Gujarat, 380015
Forest Investigative Site 607
Bangalore, Karnataka, 560003
Forest Investigative Site 606
Bangalore, Karnataka, 560010
Forest Investigative Site 602
Bangalore, Karnataka, 560043
Forest Investigative Site 604
Bangalore, Karnataka, 560092
Forest Investigative Site 603
Channi, Tamil Nadu, 600020
Forest Investigative Site 613
Chennai, Tamil Nadu, 600013
Forest Investigative Site 620
Haryāna, Karnal, 132001
Forest Investigative Site 621
Hyderabad, Andhra Pradesh, 500034
Forest Investigative Site 601
Mangalore, Karnataka, 575003
Forest Investigative Site 609
Mapusa, Goa, 403507
Forest Investigative Site 616
Nagpur, Maharashtra, 440012
Forest Investigative Site 617
Nashik, Maharashtra, 380015
Forest Investigative Site 619
Palakkad, Kerala, 678013
Forest Investigative Site 612
Pune, Maharashtra, 411037
Forest Investigative Site 615
Vellore, Tamil Nadu, 632009
Forest Investigative Site 614
Vijayawada, Andhra Pradesh, 520002
Forest Investigative Site 610
Visakhapatanam, Andhra Pradesh, 530002
Peru11 sites
Forest Investigative Site 804
Arequipa, Arequipa, 804
Forest Investigative Site 803
Arequipa, Arequipa
Forest Investigative Site 811
Chiclayo, Lambayeque
Forest Investigative Site 805
Lima, Lima Province, Lima 14
Forest Investigative Site 813
Lima, Lima Province, Lima 17
Forest Investigative Site 801
Lima, Lima Province, Lima 27
Forest Investigative Site 807
Lima, Lima Province, Lima 27
Forest Investigative Site 809
Lima, Lima Province, Lima 33
Forest Investigative Site 808
Lima, Lima Province, Lima 41
Forest Investigative Site 802
Piura, Piura
Forest Investigative Site 812
Trujillo, La Libertad
Romania7 sites
Forest Investigative Site 909
Bacau, Romania, 600164
Forest Investigative Site 906
Bucharest, Romania, 010584
Forest Investigative Site 908
Bucharest, Romania, 020725
Forest Investigative Site 903
Satu Mare, Romania, 440055
Forest Investigative Site 901
Sibiu, Romania, 550245
Forest Investigative Site 905
Tg Mures, Romania, 540142
Forest Investigative Site 902
Timișoara, Romania, 300736
Belarus5 sites
Forest Investigative Site 208
Grodno, Belarus, 230015
Forest Investigative Site 202
Homyel, Belarus, 236029
Forest Investigative Site 207
Minsk, Belarus, 220114
Forest Investigative Site 209
Mogilev, Belarus, 212030
Forest Investigative Site 206
Vitebsk, Belarus, 210037
Lithuania5 sites
Forest Investigative Site 702
Kaunas, Lithuania, 48259
Forest Investigative Site 703
Kaunas, Lithuania, 49456
Forest Investigative Site 701
Kaunas, Lithuania, 51270
Forest Investigative Site 704
Klaipėda, Lithuania, 92288
Forest Investigative Site 705
Vilnius, Lithuania, 09112
Hungary2 sites
Forest Investigative Site 506
Budapest, Hungary, H-1083
Forest Investigative Site 504
Szentes, Hungary, H-6600
About this study
Official title: A Phase III, Randomized, Double-Blind, Placebo-controlled, Multicenter Study To Evaluate The Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus on Background Treatment With Glimepiride With or Without Metformin
This study will evaluate the safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM) who are receiving background therapy of glimepiride with or without metformin.
- Conditions
- Diabetes Mellitus, Type II
- Being tested
- Dutogliptin, Placebo
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DutogliptinDrug
Dutogliptin oral administration once daily on background of glimepiride with or without metformin
PlaceboDrug
Placebo, oral administration once daily on background of glimepiride with or without metformin
| Study group | Role | What they receive |
|---|---|---|
| Dutogliptin | Active comparator | Dutogliptin Receives: Drug: Dutogliptin |
| Placebo | Placebo comparator | Placebo Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hemoglobin A1c (HbA1c)
Measured: HbA1c is drawn at Visit 1 (Week -16 to -4), Visit 3 (Week -2), Visit 4 (Week 0), Visit 5 (Week 4), Visit 6 (Week 10), Visit 7 (Week 18), Visit 8 (Week 26).
Secondary outcomes (1)
Fasting Plasma Glucose (FPG)
Measured: FPG is drawn at Visit 1 (Week -16 to -4), Visit 2 (Week -4), Visit 3 (Week -2), Visit 4 (Week 0), Visit 5 (Week 4), Visit 6 (Week 10), Visit 7 (Week 18), Visit 8 (Week 26).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2009 (estimated)
- Study startJul 2009
- Primary completionJul 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus, Type IIStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 677 participants (actual)
Sponsor and investigators
- Lead sponsor
- Forest Laboratories
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Phenomix
- Responsible party
- Sponsor
- Investigators
- Kaity Posada, PharmD, Study director, Forest Research Institute, a subsidiary of Forest Laboratories Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00947557
- Sponsor's protocol ID
- DUT-MD-303
- Status last verified
- Sep 2011
- First submitted
- 23 Jul 2009
- Last updated
- 21 Sep 2011
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III, Randomized, Double-Blind, Placebo-controlled, Multicenter Study To Evaluate The Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus on Background Treatment With Glimepiride With or Without Metformin
- ClinicalTrials.gov ID
- NCT00947557
- Acronym / sponsor ID
- DUT-MD-303
- Conditions
- Diabetes Mellitus, Type II
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 677 participants (actual)
- Lead sponsor
- Forest LaboratoriesIndustry (pharma, biotech, devices)
- Collaborators
- Phenomix
- Study start
- Jul 2009
- Primary completion
- Jul 2010 (actual)
- First posted
- 28 Jul 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM) who are receiving background therapy of glimepiride with or without metformin.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Dutogliptin | Active comparator | Drug: DutogliptinDutogliptin |
| Placebo | Placebo comparator | Drug: PlaceboPlacebo |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Type 2 diabetes mellitus, diagnosed at least 3 months prior to Screening (Visit 1)
- BMI 20 to 48 kg/m2, inclusive
- HbA1c 7.0% - 10.0%, inclusive
- Age 18 to 85 years, inclusive
Key exclusion criteria (2 listed)
- Currently on 3 or more oral antidiabetic drugs or insulin.
- Type 1 diabetes mellitus
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DutogliptinDutogliptin oral administration once daily on background of glimepiride with or without metformin | Drug | Dutogliptin |
| PlaceboPlacebo, oral administration once daily on background of glimepiride with or without metformin | Drug | Placebo |
Primary outcome
Hemoglobin A1c (HbA1c)
Time frame: HbA1c is drawn at Visit 1 (Week -16 to -4), Visit 3 (Week -2), Visit 4 (Week 0), Visit 5 (Week 4), Visit 6 (Week 10), Visit 7 (Week 18), Visit 8 (Week 26).
1 secondary outcome
Fasting Plasma Glucose (FPG)
Time frame: FPG is drawn at Visit 1 (Week -16 to -4), Visit 2 (Week -4), Visit 3 (Week -2), Visit 4 (Week 0), Visit 5 (Week 4), Visit 6 (Week 10), Visit 7 (Week 18), Visit 8 (Week 26).
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2011.
Related trials for Diabetes Mellitus, Type II
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kaity Posada, PharmD study director
Forest Research Institute, a subsidiary of Forest Laboratories Inc.
147 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Dutogliptin in people with Diabetes Mellitus, Type II, run by Forest Laboratories at 147 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 21 Sep 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 147 sites in United States, India, Peru, Romania, Belarus and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hemoglobin A1c (HbA1c) (time frame: HbA1c is drawn at Visit 1 (Week -16 to -4), Visit 3 (Week -2), Visit 4 (Week 0), Visit 5 (Week 4), Visit 6 (Week 10), Visit 7 (Week 18), Visit 8 (Week 26).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2011.